mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activity
Definition
Target type: molecularfunction
Catalysis of the endohydrolysis of the N,N'-diacetylchitobiosyl unit in high-mannose glycopeptides and glycoproteins containing the -[Man(GlcNAc)2]Asn-structure. One N-acetyl-D-glucosamine residue remains attached to the protein; the rest of the oligosaccharide is released intact. [EC:3.2.1.96]
Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activity is a molecular function that involves the hydrolysis of the beta-1,4-glycosidic bond between N-acetylglucosamine (GlcNAc) and mannose residues in N-linked glycans. Specifically, this enzyme cleaves the chitobiose core (GlcNAc-beta-1,4-GlcNAc) from the asparagine-linked oligosaccharide chains of glycoproteins. This activity is critical for the processing and degradation of glycoproteins, as it can remove glycans from glycoproteins, thereby affecting their structure, function, and stability. It plays a role in various cellular processes, including protein folding, trafficking, and degradation. In addition, it is involved in the biosynthesis of certain glycoproteins and can modify the glycosylation patterns of glycoproteins, potentially affecting their biological activity.'
"
Proteins (2)
| Protein | Definition | Taxonomy |
|---|---|---|
| Cytosolic endo-beta-N-acetylglucosaminidase | A cytosolic endo-beta-N-acetylglucosaminidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NFI3] | Homo sapiens (human) |
| Cytosolic endo-beta-N-acetylglucosaminidase | A cytosolic endo-beta-N-acetylglucosaminidase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NFI3] | Homo sapiens (human) |
Compounds (5)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| lansoprazole | Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
| omeprazole | 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole. Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
| rabeprazole | Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
| tenatoprazole | Tenatoprazole: structure in first source | imidazopyridine | |
| dexlansoprazole | Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE. | benzimidazoles; sulfoxide |